{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:46:20Z","timestamp":1790963180506,"version":"4.1.0"},"reference-count":237,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2024\/R\/1445"],"award-info":[{"award-number":["PSAU\/2024\/R\/1445"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02422-5","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:01:51Z","timestamp":1718884911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Interleukin-6 serves as a critical factor in various cancer progression and therapy"],"prefix":"10.1007","volume":"41","author":[{"given":"Asma\u2019a H.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman T.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Abdulmonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry Olegovich","family":"Bokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Riyadh Abdul Kareem","family":"Al-Hetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chou-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Chand","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Mudhafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"2422_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110153","volume":"127","author":"YB Laskar","year":"2020","unstructured":"Laskar YB, Mazumder PB. Insight into the molecular evidence supporting the remarkable chemotherapeutic potential of Hibiscus sabdariffa L. Biomed Pharmacother. 2020;127: 110153.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2422_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","volume":"15","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh MDA, et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol. 2022;15(1):83.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2422_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-022-01235-1","volume":"15","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15(1):18.","journal-title":"J Hematol Oncol"},{"key":"2422_CR4","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.2147\/CMAR.S179189","volume":"10","author":"L Browning","year":"2018","unstructured":"Browning L, et al. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685\u201393.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2422_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12931-019-1235-3","volume":"20","author":"T Aoki","year":"2019","unstructured":"Aoki T, et al. Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. Respir Res. 2019;20(1):263.","journal-title":"Respir Res"},{"issue":"1","key":"2422_CR6","first-page":"58","volume":"1","author":"C Johnson","year":"2012","unstructured":"Johnson C, et al. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58\u201370.","journal-title":"Transl Gastrointest Cancer"},{"issue":"9","key":"2422_CR7","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari N, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553\u201372.","journal-title":"Tumour Biol"},{"issue":"4","key":"2422_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2422_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","volume":"70","author":"J Wolf","year":"2014","unstructured":"Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11\u201320.","journal-title":"Cytokine"},{"issue":"3","key":"2422_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cam4.174","volume":"3","author":"O Shibayama","year":"2014","unstructured":"Shibayama O, et al. Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. Cancer Med. 2014;3(3):702\u20139.","journal-title":"Cancer Med"},{"issue":"5","key":"2422_CR11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-09-2581","volume":"16","author":"T Puchalski","year":"2010","unstructured":"Puchalski T, et al. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010;16(5):1652\u201361.","journal-title":"Clin Cancer Res"},{"issue":"36","key":"2422_CR12","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.2174\/0929867324666170712160621","volume":"25","author":"NC Kampan","year":"2018","unstructured":"Kampan NC, et al. Immunotherapeutic interleukin-6 or interleukin-6 receptor blockade in cancer: challenges and opportunities. Curr Med Chem. 2018;25(36):4785\u2013806.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2422_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4049\/jimmunol.1402908","volume":"195","author":"SS Hong","year":"2015","unstructured":"Hong SS, et al. A novel small-molecule inhibitor targeting the IL-6 receptor \u03b2 subunit, glycoprotein 130. J Immunol. 2015;195(1):237\u201345.","journal-title":"J Immunol"},{"key":"2422_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fimmu.2014.00456","volume":"5","author":"T Hirano","year":"2014","unstructured":"Hirano T. Revisiting the 1986 molecular cloning of interleukin 6. Front Immunol. 2014;5:456.","journal-title":"Front Immunol"},{"issue":"20","key":"2422_CR15","doi-asserted-by":"publisher","first-page":"11027","DOI":"10.3390\/ijms222011027","volume":"22","author":"M \u0160panko","year":"2021","unstructured":"\u0160panko M, et al. IL-6 in the ecosystem of head and neck cancer: possible therapeutic perspectives. Int J Mol Sci. 2021;22(20):11027.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2422_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348.","journal-title":"Int Immunol"},{"issue":"1","key":"2422_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cytogfr.2008.11.006","volume":"20","author":"AJP Smith","year":"2009","unstructured":"Smith AJP, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev. 2009;20(1):43\u201359.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"12","key":"2422_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5306\/wjco.v2.i12.384","volume":"2","author":"A Azevedo","year":"2011","unstructured":"Azevedo A, et al. IL-6\/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011;2(12):384\u201396.","journal-title":"World J Clin Oncol"},{"issue":"5","key":"2422_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0955-0674(98)80042-2","volume":"10","author":"RA Black","year":"1998","unstructured":"Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol. 1998;10(5):654\u20139.","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"2422_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/eji.1830230226","volume":"23","author":"J M\u00fcllberg","year":"1993","unstructured":"M\u00fcllberg J, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23(2):473\u201380.","journal-title":"Eur J Immunol"},{"issue":"6","key":"2422_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","volume":"63","author":"M Hibi","year":"1990","unstructured":"Hibi M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63(6):1149\u201357.","journal-title":"Cell"},{"issue":"1","key":"2422_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cyto.2007.07.184","volume":"39","author":"TD Vardam","year":"2007","unstructured":"Vardam TD, et al. Regulation of a lymphocyte\u2013endothelial\u2013IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance. Cytokine. 2007;39(1):84\u201396.","journal-title":"Cytokine"},{"issue":"2","key":"2422_CR23","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1074\/jbc.M109.049841","volume":"285","author":"Y Zorina","year":"2010","unstructured":"Zorina Y, Iyengar R, Bromberg KD. Cannabinoid 1 receptor and interleukin-6 receptor together induce integration of protein kinase and transcription factor signaling to trigger neurite outgrowth*. J Biol Chem. 2010;285(2):1358\u201370.","journal-title":"J Biol Chem"},{"issue":"4","key":"2422_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/ar1197","volume":"6","author":"LB Ivashkiv","year":"2004","unstructured":"Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Res Ther. 2004;6(4):159\u201368.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2422_CR25","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.7150\/ijbs.4614","volume":"8","author":"MJ Waldner","year":"2012","unstructured":"Waldner MJ, Foersch S, Neurath MF. Interleukin-6\u2013a key regulator of colorectal cancer development. Int J Biol Sci. 2012;8(9):1248\u201353.","journal-title":"Int J Biol Sci"},{"issue":"37","key":"2422_CR26","doi-asserted-by":"publisher","first-page":"9512","DOI":"10.1523\/JNEUROSCI.2160-06.2006","volume":"26","author":"T Miao","year":"2006","unstructured":"Miao T, et al. Suppressor of cytokine signaling-3 suppresses the ability of activated signal transducer and activator of transcription-3 to stimulate neurite growth in rat primary sensory neurons. J Neurosci. 2006;26(37):9512.","journal-title":"J Neurosci"},{"issue":"1","key":"2422_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, et al. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.","journal-title":"Signal Transduct Target Ther"},{"key":"2422_CR28","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","volume":"108","author":"A Masjedi","year":"2018","unstructured":"Masjedi A, et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother. 2018;108:1415\u201324.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2422_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002285","volume":"9","author":"PA Ascierto","year":"2021","unstructured":"Ascierto PA, Fu B, Wei H. IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer. 2021;9(4): e002285.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2422_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2010.03.030","volume":"636","author":"C-M Chien","year":"2010","unstructured":"Chien C-M, et al. Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor\/PI3K\/Akt signaling pathway. Eur J Pharmacol. 2010;636(1):52\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2422_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-018-0426-4","volume":"25","author":"AZ Ayob","year":"2018","unstructured":"Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.","journal-title":"J Biomed Sci"},{"issue":"5","key":"2422_CR32","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/bcr3473","volume":"15","author":"K Oh","year":"2013","unstructured":"Oh K, et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):R79.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"2422_CR33","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1002\/cam4.2327","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang J, et al. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8(10):4709\u201321.","journal-title":"Cancer Med"},{"issue":"3","key":"2422_CR34","doi-asserted-by":"publisher","first-page":"421","DOI":"10.17219\/acem\/62120","volume":"26","author":"Y Ma","year":"2017","unstructured":"Ma Y, et al. IL-6, IL-8 and TNF-\u03b1 levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017;26(3):421\u20136.","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"2422_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/jgo.2019.01.09","volume":"10","author":"R Gosain","year":"2019","unstructured":"Gosain R, et al. Interleukin-6 as a biomarker in patients with hepatobiliary cancers. J Gastrointest Oncol. 2019;10(3):537\u201345.","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"2422_CR36","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3748\/wjg.v23.i10.1780","volume":"23","author":"J Zeng","year":"2017","unstructured":"Zeng J, et al. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017;23(10):1780\u20136.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2422_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/cancers12030585","volume":"12","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, et al. Expression of interleukin-6 and the interleukin-6 receptor predicts the clinical outcomes of patients with soft tissue sarcomas. Cancers (Basel). 2020;12(3):585.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2422_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093722","volume":"5","author":"BE Lippitz","year":"2016","unstructured":"Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5(5): e1093722.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2422_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12935-022-02527-9","volume":"22","author":"NNV Radharani","year":"2022","unstructured":"Radharani NNV, et al. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int. 2022;22(1):122.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"2422_CR40","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1084\/jem.20090207","volume":"206","author":"L Wang","year":"2009","unstructured":"Wang L, et al. IL-17 can promote tumor growth through an IL-6\u2013Stat3 signaling pathway. J Exp Med. 2009;206(7):1457\u201364.","journal-title":"J Exp Med"},{"key":"2422_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7819-9-18","volume":"9","author":"P Ravishankaran","year":"2011","unstructured":"Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol. 2011;9:18.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"2422_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125\u201339.","journal-title":"Pharmacol Ther"},{"key":"2422_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/421821","volume":"2013","author":"MZ Kamran","year":"2013","unstructured":"Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013;2013: 421821.","journal-title":"Biomed Res Int"},{"issue":"4","key":"2422_CR44","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.3892\/or.2014.3366","volume":"32","author":"G Wang","year":"2014","unstructured":"Wang G, et al. Bradykinin stimulates IL-6 production and cell invasion in colorectal cancer cells. Oncol Rep. 2014;32(4):1709\u201314.","journal-title":"Oncol Rep"},{"issue":"6","key":"2422_CR45","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.3892\/ol.2016.5227","volume":"12","author":"J Han","year":"2016","unstructured":"Han J, et al. Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1\u03b1 regulation. Oncol Lett. 2016;12(6):4665\u201370.","journal-title":"Oncol Lett"},{"key":"2422_CR46","doi-asserted-by":"publisher","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177.","journal-title":"Front Oncol"},{"issue":"2","key":"2422_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41419-017-0176-3","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6\/JAK2\/STAT3 signaling. Cell Death Dis. 2018;9(2):25.","journal-title":"Cell Death Dis"},{"issue":"14","key":"2422_CR48","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.7150\/thno.85460","volume":"13","author":"A Wu","year":"2023","unstructured":"Wu A, et al. Nuclear translocation of thioredoxin-1 promotes colorectal cancer development via modulation of the IL-6\/STAT3 signaling axis through interaction with STAT3. Theranostics. 2023;13(14):4730\u201344.","journal-title":"Theranostics"},{"issue":"1","key":"2422_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12944-018-0657-0","volume":"17","author":"J Han","year":"2018","unstructured":"Han J, et al. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 2018;17(1):14.","journal-title":"Lipids Health Dis"},{"issue":"7","key":"2422_CR50","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.3390\/ijms24076650","volume":"24","author":"YH Huang","year":"2023","unstructured":"Huang YH, et al. Src-FAK signaling mediates interleukin 6-induced HCT116 colorectal cancer epithelial-mesenchymal transition. Int J Mol Sci. 2023;24(7):6650.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2422_CR51","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI73531","volume":"124","author":"M Rokavec","year":"2014","unstructured":"Rokavec M, et al. IL-6R\/STAT3\/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124(4):1853\u201367.","journal-title":"J Clin Invest"},{"key":"2422_CR52","doi-asserted-by":"publisher","first-page":"866014","DOI":"10.3389\/fonc.2022.866014","volume":"12","author":"SG Manore","year":"2022","unstructured":"Manore SG, et al. IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment. Front Oncol. 2022;12:866014.","journal-title":"Front Oncol"},{"issue":"4","key":"2422_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3816\/CBC.2002.n.008","volume":"2","author":"I Benoy","year":"2002","unstructured":"Benoy I, et al. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002;2(4):311\u20135.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"2422_CR54","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41416-018-0078-x","volume":"118","author":"R Bharti","year":"2018","unstructured":"Bharti R, et al. Differential expression of IL-6\/IL-6R and MAO-A regulates invasion\/angiogenesis in breast cancer. Br J Cancer. 2018;118(11):1442\u201352.","journal-title":"Br J Cancer"},{"issue":"64","key":"2422_CR55","doi-asserted-by":"publisher","first-page":"107844","DOI":"10.18632\/oncotarget.22253","volume":"8","author":"F Li","year":"2017","unstructured":"Li F, et al. Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer. Oncotarget. 2017;8(64):107844\u201358.","journal-title":"Oncotarget"},{"issue":"1","key":"2422_CR56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-023-01306-3","volume":"9","author":"Z Guo","year":"2023","unstructured":"Guo Z, et al. Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell Death Discov. 2023;9(1):6.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2422_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","volume":"25","author":"N Chuangchot","year":"2023","unstructured":"Chuangchot N, et al. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways. Breast Cancer Res. 2023;25(1):86.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2422_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","volume":"18","author":"YS Weng","year":"2019","unstructured":"Weng YS, et al. MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019;18(1):42.","journal-title":"Mol Cancer"},{"issue":"1","key":"2422_CR59","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.1038\/s41598-017-12017-y","volume":"7","author":"H Ogawa","year":"2017","unstructured":"Ogawa H, et al. Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells. Sci Rep. 2017;7(1):12317.","journal-title":"Sci Rep"},{"issue":"6","key":"2422_CR60","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.3892\/ol.2017.6048","volume":"13","author":"GS Shang","year":"2017","unstructured":"Shang GS, Liu L, Qin YW. IL-6 and TNF-\u03b1 promote metastasis of lung cancer by inducing epithelial-mesenchymal transition. Oncol Lett. 2017;13(6):4657\u201360.","journal-title":"Oncol Lett"},{"issue":"1","key":"2422_CR61","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13578-023-01158-5","volume":"13","author":"P Samart","year":"2023","unstructured":"Samart P, et al. Musashi-2 in cancer-associated fibroblasts promotes non-small cell lung cancer metastasis through paracrine IL-6-driven epithelial-mesenchymal transition. Cell Biosci. 2023;13(1):205.","journal-title":"Cell Biosci"},{"issue":"13","key":"2422_CR62","doi-asserted-by":"publisher","first-page":"20741","DOI":"10.18632\/oncotarget.15119","volume":"8","author":"X Wu","year":"2017","unstructured":"Wu X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2\/STAT3 signaling pathway. Oncotarget. 2017;8(13):20741\u201350.","journal-title":"Oncotarget"},{"key":"2422_CR63","first-page":"8334881","volume":"2023","author":"T Zhang","year":"2023","unstructured":"Zhang T, et al. Interleukin-6 and hypoxia synergistically promote EMT-mediated invasion in epithelial ovarian cancer via the IL-6\/STAT3\/HIF-1\u03b1 feedback loop. Anal Cell Pathol (Amst). 2023;2023:8334881.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"2422_CR64","doi-asserted-by":"crossref","first-page":"2390125","DOI":"10.1155\/2020\/2390125","volume":"2020","author":"C Chen","year":"2020","unstructured":"Chen C, et al. Antiangiogenesis efficacy of ethanol extract from Amomum tsaoko in ovarian cancer through inducing ER stress to suppress p-STAT3\/NF-kB\/IL-6 and VEGF Loop. Evid Based Compl Alternat Med. 2020;2020:2390125.","journal-title":"Evid Based Compl Alternat Med"},{"issue":"1","key":"2422_CR65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s13046-019-1394-6","volume":"38","author":"A Shang","year":"2019","unstructured":"Shang A, et al. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J Exp Clin Cancer Res. 2019;38(1):411.","journal-title":"J Exp Clin Cancer Res"},{"key":"2422_CR66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2021.12.011","volume":"527","author":"M Li","year":"2022","unstructured":"Li M, et al. Interleukin-6 facilitates tumor progression by inducing ferroptosis resistance in head and neck squamous cell carcinoma. Cancer Lett. 2022;527:28\u201340.","journal-title":"Cancer Lett"},{"issue":"3","key":"2422_CR67","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/cas.14752","volume":"112","author":"GQ Zhang","year":"2021","unstructured":"Zhang GQ, et al. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. Cancer Sci. 2021;112(3):997\u20131010.","journal-title":"Cancer Sci"},{"issue":"5","key":"2422_CR68","first-page":"423","volume":"11","author":"PC Hsu","year":"2021","unstructured":"Hsu PC, et al. Interleukin-6 and interleukin-8 regulate STAT3 activation migration\/invasion and EMT in chrysophanol-treated oral cancer cell lines. Life (Basel). 2021;11(5):423.","journal-title":"Life (Basel)"},{"issue":"1","key":"2422_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/19336918.2017.1307482","volume":"12","author":"Y Chen","year":"2018","unstructured":"Chen Y, et al. IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells. Cell Adh Migr. 2018;12(1):28\u201336.","journal-title":"Cell Adh Migr"},{"issue":"4","key":"2422_CR70","first-page":"255","volume":"39","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. IL-6 accelerates the proliferation and metastasis of pancreatic cancer cells via the miR-455-5p\/IGF-1R axis. Cancer Biother Radiopharm. 2022;39(4):255\u201363.","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"2422_CR71","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cancers14071732","volume":"14","author":"MS Hossain","year":"2022","unstructured":"Hossain MS, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14(7):1732.","journal-title":"Cancers (Basel)"},{"key":"2422_CR72","doi-asserted-by":"publisher","first-page":"13023","DOI":"10.2147\/OTT.S278013","volume":"13","author":"Y Lin","year":"2020","unstructured":"Lin Y, et al. Progress in understanding the IL-6\/STAT3 pathway in colorectal cancer. Onco Targets Ther. 2020;13:13023\u201332.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"2422_CR73","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000350836","volume":"84","author":"J Shimazaki","year":"2013","unstructured":"Shimazaki J, et al. In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte\/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression. Oncology. 2013;84(6):356\u201361.","journal-title":"Oncology"},{"key":"2422_CR74","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/cells11071164","volume":"11","author":"PB Sehgal","year":"2022","unstructured":"Sehgal PB. Interleukin-6 at the host-tumor interface: STAT3 in biomolecular condensates in cancer cells. Cells. 2022;11:1164. https:\/\/doi.org\/10.3390\/cells11071164.","journal-title":"Cells"},{"issue":"5","key":"2422_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/jir.2005.25.241","volume":"25","author":"SA Jones","year":"2005","unstructured":"Jones SA, et al. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25(5):241\u201353.","journal-title":"J Interferon Cytokine Res"},{"issue":"17","key":"2422_CR76","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2422_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1875","volume":"7","author":"M Khanom","year":"2024","unstructured":"Khanom M, et al. The linkage between IL-6 rs1800797 variant and breast cancer susceptibility in Bangladeshi women: a case-control study. Health Sci Rep. 2024;7(2): e1875.","journal-title":"Health Sci Rep"},{"issue":"3","key":"2422_CR78","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-023-07086-9","volume":"202","author":"A Bun","year":"2023","unstructured":"Bun A, et al. Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin. Breast Cancer Res Treat. 2023;202(3):575\u201383.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2422_CR79","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13046-018-0867-3","volume":"37","author":"HS Kim","year":"2018","unstructured":"Kim HS, et al. IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression. J Exp Clin Cancer Res. 2018;37(1):200.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2422_CR80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13046-023-02620-5","volume":"42","author":"B Zhou","year":"2023","unstructured":"Zhou B, et al. Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-. J Exp Clin Cancer Res. 2023;42(1):48.","journal-title":"J Exp Clin Cancer Res"},{"issue":"24","key":"2422_CR81","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.3390\/cancers15245757","volume":"15","author":"K Berger","year":"2023","unstructured":"Berger K, et al. Interleukin-6 induces stem cell propagation through Liaison with the Sortilin-Progranulin Axis in Breast Cancer. Cancers (Basel). 2023;15(24):5757.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2422_CR82","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13058-023-01642-3","volume":"25","author":"H Liu","year":"2023","unstructured":"Liu H, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6\/STAT3 signaling. Breast Cancer Res. 2023;25(1):43.","journal-title":"Breast Cancer Res"},{"key":"2422_CR83","doi-asserted-by":"publisher","first-page":"107327482110686","DOI":"10.1177\/10732748211068637","volume":"29","author":"A Aguilar","year":"2022","unstructured":"Aguilar A, et al. Impact of targeted therapy on the survival of patients with advanced-stage non-small cell lung cancer in oncosalud\u2014AUNA. Cancer Control. 2022;29:10732748211068636.","journal-title":"Cancer Control"},{"issue":"1","key":"2422_CR84","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12916-022-02356-7","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu C, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022;20(1):187.","journal-title":"BMC Med"},{"issue":"3","key":"2422_CR85","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/1535-7163.MCT-10-0502","volume":"10","author":"L Song","year":"2011","unstructured":"Song L, et al. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther. 2011;10(3):481\u201394.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2422_CR86","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41389-023-00463-5","volume":"12","author":"C Sun","year":"2023","unstructured":"Sun C, et al. Transgelin promotes lung cancer progression via activation of cancer-associated fibroblasts with enhanced IL-6 release. Oncogenesis. 2023;12(1):18.","journal-title":"Oncogenesis"},{"key":"2422_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122111","volume":"332","author":"Y Lu","year":"2023","unstructured":"Lu Y, et al. Nickel chloride promotes lung cancer invasion and metastasis by up-regulating the expression of E3 ubiquitin ligase TRIM31 through the IL-6\/STAT3 signaling axis. Life Sci. 2023;332: 122111.","journal-title":"Life Sci"},{"issue":"2","key":"2422_CR88","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41419-024-06495-y","volume":"15","author":"X Jin","year":"2024","unstructured":"Jin X, et al. Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2\/STAT3 signaling via transactivation of IL-6ST and IL-6 genes. Cell Death Dis. 2024;15(2):148.","journal-title":"Cell Death Dis"},{"issue":"7","key":"2422_CR89","first-page":"2886","volume":"13","author":"C Ye","year":"2023","unstructured":"Ye C, et al. Suppression of tumorigenesis in LUAD by LRP1B through regulation of the IL-6-JAK-STAT3 pathway. Am J Cancer Res. 2023;13(7):2886\u2013905.","journal-title":"Am J Cancer Res"},{"key":"2422_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.804418","volume":"11","author":"L Han","year":"2021","unstructured":"Han L, et al. Agrin promotes non-small cell lung cancer progression and stimulates regulatory T cells via increasing IL-6 secretion through PI3K\/AKT pathway. Front Oncol. 2021;11: 804418.","journal-title":"Front Oncol"},{"key":"2422_CR91","doi-asserted-by":"publisher","first-page":"153303382210903","DOI":"10.1177\/15330338221090353","volume":"21","author":"T Li","year":"2022","unstructured":"Li T, et al. Advances in treatment models of advanced gastric cancer. Technol Cancer Res Treat. 2022;21:15330338221090352.","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"2422_CR92","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x2020e10687","volume":"54","author":"MP Santos","year":"2021","unstructured":"Santos MP, et al. Increased expression of interleukin-6 gene in gastritis and gastric cancer. Braz J Med Biol Res. 2021;54(7): e10687.","journal-title":"Braz J Med Biol Res"},{"issue":"43","key":"2422_CR93","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031514","volume":"101","author":"Y Hou","year":"2022","unstructured":"Hou Y, et al. Serum amyloid A (SAA) and Interleukin-6 (IL-6) as the potential biomarkers for gastric cancer. Medicine (Baltimore). 2022;101(43): e31514.","journal-title":"Medicine (Baltimore)"},{"key":"2422_CR94","doi-asserted-by":"publisher","first-page":"175628482312115","DOI":"10.1177\/17562848231211543","volume":"16","author":"P Liang","year":"2023","unstructured":"Liang P, et al. Association between IL-6 and prognosis of gastric cancer: a retrospective study. Therap Adv Gastroenterol. 2023;16:17562848231211544.","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"2422_CR95","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12885-022-10332-w","volume":"23","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, et al. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer-associated fibroblast-related gene signature for predicting survival and therapy in gastric cancer. BMC Cancer. 2023;23(1):108.","journal-title":"BMC Cancer"},{"key":"2422_CR96","doi-asserted-by":"publisher","first-page":"10567","DOI":"10.2147\/OTT.S266506","volume":"13","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Bone marrow-derived myofibroblasts promote gastric cancer metastasis by activating TGF-\u03b21 and IL-6\/STAT3 signalling loop. Onco Targets Ther. 2020;13:10567\u201380.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"2422_CR97","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41419-022-04747-3","volume":"13","author":"M Liu","year":"2022","unstructured":"Liu M, et al. RBMS1 promotes gastric cancer metastasis through autocrine IL-6\/JAK2\/STAT3 signaling. Cell Death Dis. 2022;13(3):287.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2422_CR98","doi-asserted-by":"publisher","first-page":"19427","DOI":"10.1038\/s41598-022-24189-3","volume":"12","author":"L Zhou","year":"2022","unstructured":"Zhou L, et al. IL-6\/IL-10 mRNA expression ratio in tumor tissues predicts prognosis in gastric cancer patients without distant metastasis. Sci Rep. 2022;12(1):19427.","journal-title":"Sci Rep"},{"issue":"9","key":"2422_CR99","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/2211-5463.13270","volume":"11","author":"H Fan","year":"2021","unstructured":"Fan H, et al. ZIPK activates the IL-6\/STAT3 signaling pathway and promotes cisplatin resistance in gastric cancer cells. FEBS Open Bio. 2021;11(9):2655\u201367.","journal-title":"FEBS Open Bio"},{"issue":"2","key":"2422_CR100","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41388-023-02885-2","volume":"43","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, et al. VPS35 promotes gastric cancer progression through integrin\/FAK\/SRC signalling-mediated IL-6\/STAT3 pathway activation in a YAP-dependent manner. Oncogene. 2024;43(2):106\u201322.","journal-title":"Oncogene"},{"issue":"4","key":"2422_CR101","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/cells11040650","volume":"11","author":"S Akter","year":"2022","unstructured":"Akter S, et al. Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements. Cells. 2022;11(4):650.","journal-title":"Cells"},{"issue":"2","key":"2422_CR102","doi-asserted-by":"publisher","first-page":"188639","DOI":"10.1016\/j.bbcan.2021.188639","volume":"1876","author":"I Szulc-Kielbik","year":"2021","unstructured":"Szulc-Kielbik I, et al. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188639.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2422_CR103","doi-asserted-by":"publisher","first-page":"7689","DOI":"10.1038\/s41598-021-86913-9","volume":"11","author":"T Seki","year":"2021","unstructured":"Seki T, et al. Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma. Sci Rep. 2021;11(1):7689.","journal-title":"Sci Rep"},{"key":"2422_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108334","volume":"684","author":"H Zhang","year":"2020","unstructured":"Zhang H, et al. IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells. Arch Biochem Biophys. 2020;684: 108334.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"2422_CR105","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13048-020-00672-1","volume":"13","author":"J Ge","year":"2020","unstructured":"Ge J, et al. Long non-coding RNA THOR promotes ovarian Cancer cells progression via IL-6\/STAT3 pathway. J Ovarian Res. 2020;13(1):72.","journal-title":"J Ovarian Res"},{"issue":"6","key":"2422_CR106","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/jpm13060980","volume":"13","author":"M Bizo\u0144","year":"2023","unstructured":"Bizo\u0144 M, Awi\u017ce\u0144-Panufnik Z, Sawicki W. Comparison of interleukin-6 with other markers in diagnosis of ovarian cancer. J Pers Med. 2023;13(6):980.","journal-title":"J Pers Med"},{"key":"2422_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156073","volume":"161","author":"A Pa\u0219ca","year":"2023","unstructured":"Pa\u0219ca A, et al. Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. Cytokine. 2023;161: 156073.","journal-title":"Cytokine"},{"issue":"5","key":"2422_CR108","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1080\/08820139.2019.1691222","volume":"49","author":"ISS Rodrigues","year":"2020","unstructured":"Rodrigues ISS, et al. IL-6 and IL-8 as prognostic factors in peritoneal fluid of ovarian cancer. Immunol Invest. 2020;49(5):510\u201321.","journal-title":"Immunol Invest"},{"issue":"6","key":"2422_CR109","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13309","volume":"84","author":"PCA Crispim","year":"2020","unstructured":"Crispim PCA, et al. IL6, IL8, and IL10 in the distinction of malignant ovarian neoplasms and endometriomas. Am J Reprod Immunol. 2020;84(6): e13309.","journal-title":"Am J Reprod Immunol"},{"key":"2422_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101426","volume":"21","author":"B Goel","year":"2022","unstructured":"Goel B, et al. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma\u2014an update on clinical trials. Transl Oncol. 2022;21: 101426.","journal-title":"Transl Oncol"},{"issue":"5","key":"2422_CR111","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00259-021-05602-x","volume":"49","author":"A R\u00fchle","year":"2022","unstructured":"R\u00fchle A, et al. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial. Eur J Nucl Med Mol Imaging. 2022;49(5):1650\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2422_CR112","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3389\/fonc.2018.00310","volume":"8","author":"MD Forster","year":"2018","unstructured":"Forster MD, Devlin MJ. Immune checkpoint inhibition in head and neck cancer. Front Oncol. 2018;8:310.","journal-title":"Front Oncol"},{"key":"2422_CR113","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.oraloncology.2019.02.027","volume":"91","author":"M-S Tsai","year":"2019","unstructured":"Tsai M-S, et al. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling. Oral Oncol. 2019;91:47\u201355.","journal-title":"Oral Oncol"},{"key":"2422_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111200","volume":"126","author":"M Jiang","year":"2024","unstructured":"Jiang M, et al. HMGB1-activated tumor-associated macrophages promote migration and invasion via NF-\u03baB\/IL-6 signaling in oral squamous cell carcinoma. Int Immunopharmacol. 2024;126: 111200.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2422_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262549","volume":"17","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, et al. Irradiated fibroblasts increase interleukin-6 expression and induce migration of head and neck squamous cell carcinoma. PLoS ONE. 2022;17(1): e0262549.","journal-title":"PLoS ONE"},{"issue":"1","key":"2422_CR116","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21053\/ceo.2019.00906","volume":"14","author":"U Uz","year":"2021","unstructured":"Uz U, Eskiizmir G. Association between interleukin-6 and head and neck squamous cell carcinoma: a systematic review. Clin Exp Otorhinolaryngol. 2021;14(1):50\u201360.","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"11","key":"2422_CR117","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41419-021-04268-5","volume":"12","author":"AE Herzog","year":"2021","unstructured":"Herzog AE, et al. The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death Dis. 2021;12(11):988.","journal-title":"Cell Death Dis"},{"key":"2422_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106822","volume":"194","author":"M Ashrafizadeh","year":"2023","unstructured":"Ashrafizadeh M, et al. A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: complexity and simplicity in crosstalk. Pharmacol Res. 2023;194: 106822.","journal-title":"Pharmacol Res"},{"key":"2422_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216733","volume":"587","author":"J Yuan","year":"2024","unstructured":"Yuan J, et al. SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation. Cancer Lett. 2024;587: 216733.","journal-title":"Cancer Lett"},{"issue":"11","key":"2422_CR120","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00520-013-1878-4","volume":"21","author":"S-Y Suh","year":"2013","unstructured":"Suh S-Y, et al. Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. Support Care Cancer. 2013;21(11):3071\u20137.","journal-title":"Support Care Cancer"},{"issue":"6","key":"2422_CR121","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s002689910110","volume":"24","author":"MD Barber","year":"2000","unstructured":"Barber MD, Ross JA, Fearon KCH. Disordered metabolic response with cancer and its management. World J Surg. 2000;24(6):681\u20139.","journal-title":"World J Surg"},{"issue":"4","key":"2422_CR122","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","volume":"19","author":"M Lesina","year":"2011","unstructured":"Lesina M, et al. Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011;19(4):456\u201369.","journal-title":"Cancer Cell"},{"issue":"24","key":"2422_CR123","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1002\/cam4.4823","volume":"11","author":"H Suzuki","year":"2022","unstructured":"Suzuki H, et al. Interleukin 6\/gp130 axis promotes neural invasion in pancreatic cancer. Cancer Med. 2022;11(24):5001\u201312.","journal-title":"Cancer Med"},{"issue":"12","key":"2422_CR124","first-page":"5992","volume":"11","author":"S Wang","year":"2021","unstructured":"Wang S, et al. Paracrine production of IL-6 promotes a hypercoagulable state in pancreatic cancer. Am J Cancer Res. 2021;11(12):5992\u20136003.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2422_CR125","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bjc.2013.748","volume":"110","author":"T Nagasaki","year":"2014","unstructured":"Nagasaki T, et al. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour\u2013stroma interaction. Br J Cancer. 2014;110(2):469\u201378.","journal-title":"Br J Cancer"},{"issue":"10","key":"2422_CR126","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1172\/JCI35213","volume":"118","author":"M Kujawski","year":"2008","unstructured":"Kujawski M, et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118(10):3367\u201377.","journal-title":"J Clin Invest"},{"issue":"12","key":"2422_CR127","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1172\/JCI32533","volume":"117","author":"P Sansone","year":"2007","unstructured":"Sansone P, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988\u20134002.","journal-title":"J Clin Invest"},{"issue":"3","key":"2422_CR128","first-page":"269","volume":"33","author":"S Luan","year":"2018","unstructured":"Luan S, et al. Interleukin 6 receptor (IL-6R) was an independent prognostic factor in cervical cancer. Histol Histopathol. 2018;33(3):269\u201376.","journal-title":"Histol Histopathol"},{"issue":"1","key":"2422_CR129","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3892\/ol.2020.12317","volume":"21","author":"MS Sohn","year":"2021","unstructured":"Sohn MS, et al. Downregulation of APRIN expression increases cancer cell proliferation via an interleukin-6\/STAT3\/cyclin D axis. Oncol Lett. 2021;21(1):55.","journal-title":"Oncol Lett"},{"issue":"1","key":"2422_CR130","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/jir.2020.0193","volume":"41","author":"X Li","year":"2021","unstructured":"Li X, et al. CCDC68 Upregulation by IL-6 Promotes Endometrial Carcinoma Progression. J Interferon Cytokine Res. 2021;41(1):12\u20139.","journal-title":"J Interferon Cytokine Res"},{"key":"2422_CR131","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.2147\/OTT.S262089","volume":"13","author":"Y Li","year":"2020","unstructured":"Li Y, et al. IL-6\/STAT3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells. Onco Targets Ther. 2020;13:9721\u201330.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2422_CR132","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.3390\/ijms21051723","volume":"21","author":"Z Ali Syeda","year":"2020","unstructured":"Ali Syeda Z, et al. Regulatory mechanism of microRNA expression in cancer. Int J Mol Sci. 2020;21(5):1723.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2422_CR133","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.3748\/wjg.v19.i20.2985","volume":"19","author":"J Raisch","year":"2013","unstructured":"Raisch J, Darfeuille-Michaud A, Nguyen HT. Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol. 2013;19(20):2985\u201396.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2422_CR134","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-017-0710-z","volume":"16","author":"Y Yang","year":"2017","unstructured":"Yang Y, et al. MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6\/STAT3 and negatively correlates with poor prognosis. Mol Cancer. 2017;16(1):141.","journal-title":"Mol Cancer"},{"key":"2422_CR135","doi-asserted-by":"crossref","unstructured":"Xiang T, et al. The circular RNA circFOXK2 enhances the tumorigenesis of non-small cell lung cancer through the miR-149\u20133p\/IL-6 Axis. Biochem Genet. 2024;62(1):95\u2013111.","DOI":"10.1007\/s10528-023-10394-w"},{"key":"2422_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109876","volume":"125","author":"N Wang","year":"2020","unstructured":"Wang N, et al. CircRBM33 regulates IL-6 to promote gastric cancer progression through targeting miR-149. Biomed Pharmacother. 2020;125: 109876.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2422_CR137","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.5114\/aoms\/154956","volume":"18","author":"C Yang","year":"2022","unstructured":"Yang C, Deng S. Hsa_circ_0017728 as an oncogene in gastric cancer by sponging miR-149 and modulating the IL-6\/STAT3 pathway. Arch Med Sci. 2022;18(6):1558\u201371.","journal-title":"Arch Med Sci"},{"issue":"5","key":"2422_CR138","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.7150\/thno.53169","volume":"11","author":"G Lu","year":"2021","unstructured":"Lu G, et al. NEK9, a novel effector of IL-6\/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation. Theranostics. 2021;11(5):2460\u201374.","journal-title":"Theranostics"},{"issue":"1","key":"2422_CR139","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep.26305","volume":"58","author":"X Yang","year":"2013","unstructured":"Yang X, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 2013;58(1):158\u201370.","journal-title":"Hepatology"},{"key":"2422_CR140","doi-asserted-by":"publisher","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J, et al. IL-6\/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma. Front Oncol. 2021;11:760971.","journal-title":"Front Oncol"},{"issue":"4","key":"2422_CR141","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","volume":"12","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464\u201370.","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"2422_CR142","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/JTO.0000000000000193","volume":"9","author":"L Song","year":"2014","unstructured":"Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014;9(7):974\u201382.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"2422_CR143","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","volume":"16","author":"Y Guo","year":"2010","unstructured":"Guo Y, et al. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010;16(23):5759\u201369.","journal-title":"Clin Cancer Res"},{"key":"2422_CR144","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/978-0-387-69080-3_56","volume":"617","author":"IT Cavarretta","year":"2008","unstructured":"Cavarretta IT, et al. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. Adv Exp Med Biol. 2008;617:547\u201355.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"2422_CR145","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","volume":"103","author":"JF Rossi","year":"2010","unstructured":"Rossi JF, et al. A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103(8):1154\u201362.","journal-title":"Br J Cancer"},{"issue":"3","key":"2422_CR146","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clml.2012.12.010","volume":"13","author":"A Chari","year":"2013","unstructured":"Chari A, Pri-Chen H, Jagannath S. Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk. 2013;13(3):333\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2422_CR147","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ajh.23868","volume":"90","author":"RZ Orlowski","year":"2015","unstructured":"Orlowski RZ, et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 2015;90(1):42\u20139.","journal-title":"Am J Hematol"},{"issue":"5","key":"2422_CR148","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2141.2010.08533.x","volume":"152","author":"SA Hunsucker","year":"2011","unstructured":"Hunsucker SA, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol. 2011;152(5):579\u201392.","journal-title":"Br J Haematol"},{"issue":"1","key":"2422_CR149","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","volume":"48","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2012;48(1):85\u201393.","journal-title":"Eur J Cancer"},{"issue":"23","key":"2422_CR150","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","volume":"15","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15(23):7144\u201352.","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"2422_CR151","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/jco.2009.27.15_suppl.3025","volume":"27","author":"SJ Clarke","year":"2009","unstructured":"Clarke SJ, et al. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol. 2009;27(15_suppl):3025\u20133025.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2422_CR152","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","volume":"11","author":"TJ Bayliss","year":"2011","unstructured":"Bayliss TJ, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11(12):1663\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2422_CR153","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bjc.2013.748","volume":"110","author":"T Nagasaki","year":"2014","unstructured":"Nagasaki T, et al. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 2014;110(2):469\u201378.","journal-title":"Br J Cancer"},{"issue":"7","key":"2422_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102436","volume":"9","author":"K Ando","year":"2014","unstructured":"Ando K, et al. Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer. PLoS ONE. 2014;9(7): e102436.","journal-title":"PLoS ONE"},{"issue":"2","key":"2422_CR155","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cdd.2017.162","volume":"25","author":"D Wang","year":"2018","unstructured":"Wang D, et al. IL6 blockade potentiates the anti-tumor effects of \u03b3-secretase inhibitors in Notch3-expressing breast cancer. Cell Death Differ. 2018;25(2):330\u20139.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2422_CR156","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1111\/cas.15929","volume":"114","author":"S Mitsunaga","year":"2023","unstructured":"Mitsunaga S, et al. Fibroblast inhibition by tocilizumab enabled gemcitabine\/nab-paclitaxel rechallenge for pancreatic cancer. Cancer Sci. 2023;114(10):4006\u201319.","journal-title":"Cancer Sci"},{"issue":"6","key":"2422_CR157","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","volume":"31","author":"K Ando","year":"2013","unstructured":"Ando K, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013;31(6):e69-72.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2422_CR158","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf EM, et al. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015;26(10):2141\u20139.","journal-title":"Ann Oncol"},{"issue":"20","key":"2422_CR159","first-page":"4633","volume":"55","author":"N Borsellino","year":"1995","unstructured":"Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995;55(20):4633\u20139.","journal-title":"Cancer Res"},{"key":"2422_CR160","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","volume":"180","author":"IM Chen","year":"2023","unstructured":"Chen IM, et al. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Eur J Cancer. 2023;180:125\u201333.","journal-title":"Eur J Cancer"},{"issue":"17","key":"2422_CR161","doi-asserted-by":"publisher","first-page":"13743","DOI":"10.1074\/jbc.M112.349167","volume":"287","author":"J Sommer","year":"2012","unstructured":"Sommer J, et al. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem. 2012;287(17):13743\u201351.","journal-title":"J Biol Chem"},{"issue":"6","key":"2422_CR162","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1158\/1535-7163.MCT-12-1082","volume":"12","author":"S Xu","year":"2013","unstructured":"Xu S, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol Cancer Ther. 2013;12(6):937\u201349.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2422_CR163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa062462","volume":"355","author":"E Barrett-Connor","year":"2006","unstructured":"Barrett-Connor E, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125\u201337.","journal-title":"N Engl J Med"},{"issue":"2","key":"2422_CR164","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1210\/en.2012-2038","volume":"154","author":"Y Song","year":"2013","unstructured":"Song Y, et al. Inhibitory effects of a bazedoxifene\/conjugated equine estrogen combination on human breast cancer cells in vitro. Endocrinology. 2013;154(2):656\u201365.","journal-title":"Endocrinology"},{"issue":"1","key":"2422_CR165","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00432-022-04518-9","volume":"149","author":"I Pozios","year":"2023","unstructured":"Pozios I, et al. Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144. J Cancer Res Clin Oncol. 2023;149(1):271\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2422_CR166","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/cancers15020456","volume":"15","author":"NA Hering","year":"2023","unstructured":"Hering NA, et al. Targeting interleukin-6\/glycoprotein-130 signaling by raloxifene or SC144 enhances paclitaxel efficacy in pancreatic cancer. Cancers (Basel). 2023;15(2):456.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2422_CR167","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/JTO.0b013e31820d9d11","volume":"6","author":"Y Sun","year":"2011","unstructured":"Sun Y, et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol. 2011;6(4):699\u2013706.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2422_CR168","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1535-7163.MCT-11-0951","volume":"11","author":"MM Seavey","year":"2012","unstructured":"Seavey MM, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther. 2012;11(4):984\u201393.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2422_CR169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095993","volume":"9","author":"LM Judd","year":"2014","unstructured":"Judd LM, et al. Inhibition of the JAK2\/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS ONE. 2014;9(5): e95993.","journal-title":"PLoS ONE"},{"issue":"1","key":"2422_CR170","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-9966-29-51","volume":"29","author":"C Huang","year":"2010","unstructured":"Huang C, et al. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010;29(1):51.","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"2422_CR171","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in Myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"2422_CR172","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","volume":"15","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, et al. A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(3):171\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2422_CR173","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1002\/cam4.1703","volume":"7","author":"D Fogelman","year":"2018","unstructured":"Fogelman D, et al. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed\/refractory metastatic colorectal cancer. Cancer Med. 2018;7(11):5382\u201393.","journal-title":"Cancer Med"},{"key":"2422_CR174","doi-asserted-by":"publisher","first-page":"1136114","DOI":"10.3389\/fphar.2023.1136114","volume":"14","author":"T Yuan","year":"2023","unstructured":"Yuan T, et al. Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer. Front Pharmacol. 2023;14:1136114.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2422_CR175","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1186\/s12877-022-03637-9","volume":"22","author":"B Chen","year":"2022","unstructured":"Chen B, et al. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer. BMC Geriatr. 2022;22(1):987.","journal-title":"BMC Geriatr"},{"key":"2422_CR176","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","volume":"169","author":"RD Kim","year":"2022","unstructured":"Kim RD, et al. A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022;169:93\u2013102.","journal-title":"Eur J Cancer"},{"issue":"10","key":"2422_CR177","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S1470-2045(23)00358-3","volume":"24","author":"SL Cytryn","year":"2023","unstructured":"Cytryn SL, et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2023;24(10):1073\u201382.","journal-title":"Lancet Oncol"},{"issue":"13\u201314","key":"2422_CR178","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/scd.2022.0088","volume":"31","author":"M Zhang","year":"2022","unstructured":"Zhang M, et al. Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation. Stem Cells Dev. 2022;31(13\u201314):383\u201394.","journal-title":"Stem Cells Dev"},{"issue":"4","key":"2422_CR179","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41419-022-04816-7","volume":"13","author":"YC Chang","year":"2022","unstructured":"Chang YC, et al. Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. Cell Death Dis. 2022;13(4):391.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2422_CR180","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/ijms24010686","volume":"24","author":"D Sharma","year":"2022","unstructured":"Sharma D, et al. Regorafenib and ruthenium complex combination inhibit cancer cell growth by targeting PI3K\/AKT\/ERK signalling in colorectal cancer cells. Int J Mol Sci. 2022;24(1):686.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2422_CR181","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1158\/1535-7163.MCT-10-0550","volume":"9","author":"G Ishdorj","year":"2010","unstructured":"Ishdorj G, Johnston JB, Gibson SB. Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-leukemia cells to apoptosis. Mol Cancer Ther. 2010;9(12):3302\u201314.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"2422_CR182","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.1016\/j.bmcl.2010.09.117","volume":"20","author":"G Zinzalla","year":"2010","unstructured":"Zinzalla G, et al. A novel small-molecule inhibitor of IL-6 signalling. Bioorg Med Chem Lett. 2010;20(23):7029\u201332.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"2422_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128406","volume":"10","author":"X Yu","year":"2015","unstructured":"Yu X, et al. Eriocalyxin B inhibits STAT3 signaling by covalently targeting STAT3 and blocking phosphorylation and activation of STAT3. PLoS ONE. 2015;10(5): e0128406.","journal-title":"PLoS ONE"},{"issue":"48","key":"2422_CR184","doi-asserted-by":"publisher","first-page":"45443","DOI":"10.1074\/jbc.M107527200","volume":"276","author":"J Turkson","year":"2001","unstructured":"Turkson J, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem. 2001;276(48):45443\u201355.","journal-title":"J Biol Chem"},{"issue":"3","key":"2422_CR185","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1158\/1535-7163.261.3.3","volume":"3","author":"J Turkson","year":"2004","unstructured":"Turkson J, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004;3(3):261\u20139.","journal-title":"Mol Cancer Ther"},{"key":"2422_CR186","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1476-4598-7-78","volume":"7","author":"CL Chen","year":"2008","unstructured":"Chen CL, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 2008;7:78.","journal-title":"Mol Cancer"},{"issue":"13","key":"2422_CR187","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1073\/pnas.0409894102","volume":"102","author":"H Song","year":"2005","unstructured":"Song H, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 2005;102(13):4700\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2422_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.836724","volume":"13","author":"Y Hua","year":"2022","unstructured":"Hua Y, et al. Novel STAT3 inhibitors targeting STAT3 dimerization by binding to the STAT3 SH2 domain. Front Pharmacol. 2022;13: 836724.","journal-title":"Front Pharmacol"},{"key":"2422_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.116941","volume":"71","author":"H Li","year":"2022","unstructured":"Li H, et al. S3I\u2013201 derivative incorporating naphthoquinone unit as effective STAT3 inhibitors: design, synthesis and anti-gastric cancer evaluation. Bioorg Med Chem. 2022;71: 116941.","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"2422_CR190","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/1078-0432.CCR-22-0997","volume":"29","author":"H Chen","year":"2023","unstructured":"Chen H, et al. Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic cancer. Clin Cancer Res. 2023;29(4):815\u201330.","journal-title":"Clin Cancer Res"},{"key":"2422_CR191","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116040","volume":"221","author":"J Yang","year":"2024","unstructured":"Yang J, et al. WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin. Biochem Pharmacol. 2024;221: 116040.","journal-title":"Biochem Pharmacol"},{"issue":"18","key":"2422_CR192","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1158\/0008-5472.CAN-03-4041","volume":"64","author":"N Jing","year":"2004","unstructured":"Jing N, et al. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 2004;64(18):6603\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"2422_CR193","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/13543780802565791","volume":"18","author":"P Yue","year":"2009","unstructured":"Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs. 2009;18(1):45\u201356.","journal-title":"Expert Opin Investig Drugs"},{"issue":"27","key":"2422_CR194","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1038\/onc.2014.286","volume":"34","author":"V De Simone","year":"2015","unstructured":"De Simone V, et al. Th17-type cytokines, IL-6 and TNF-\u03b1 synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34(27):3493\u2013503.","journal-title":"Oncogene"},{"issue":"3","key":"2422_CR195","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.chembiol.2021.10.006","volume":"29","author":"L Sun","year":"2022","unstructured":"Sun L, et al. Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth. Cell Chem Biol. 2022;29(3):373-385.e6.","journal-title":"Cell Chem Biol"},{"key":"2422_CR196","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.870367","volume":"13","author":"D Yu","year":"2022","unstructured":"Yu D, et al. Inhibition of STAT3 signaling pathway by terphenyllin suppresses growth and metastasis of gastric cancer. Front Pharmacol. 2022;13: 870367.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2422_CR197","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10549-022-06790-2","volume":"197","author":"Z Yang","year":"2023","unstructured":"Yang Z, et al. Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis. Breast Cancer Res Treat. 2023;197(2):255\u201367.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2422_CR198","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00280-014-2480-2","volume":"74","author":"JC Bendell","year":"2014","unstructured":"Bendell JC, et al. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(1):125\u201330.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2422_CR199","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4143\/crt.2014.249","volume":"47","author":"DY Oh","year":"2015","unstructured":"Oh DY, et al. Phase I study of OPB-31121, an Oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat. 2015;47(4):607\u201315.","journal-title":"Cancer Res Treat"},{"issue":"13","key":"2422_CR200","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/hepr.12504","volume":"45","author":"T Okusaka","year":"2015","unstructured":"Okusaka T, et al. Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res. 2015;45(13):1283\u201391.","journal-title":"Hepatol Res"},{"issue":"9","key":"2422_CR201","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2422_CR202","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40265-014-0249-x","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A, Patel T. Siltuximab: first global approval. Drugs. 2014;74(10):1147\u201352.","journal-title":"Drugs"},{"issue":"13","key":"2422_CR203","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/pros.21362","volume":"71","author":"J Karkera","year":"2011","unstructured":"Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011;71(13):1455\u201365.","journal-title":"Prostate"},{"issue":"3","key":"2422_CR204","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10637-012-9857-z","volume":"31","author":"G Hudes","year":"2013","unstructured":"Hudes G, et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest New Drugs. 2013;31(3):669\u201376.","journal-title":"Invest New Drugs"},{"issue":"7","key":"2422_CR205","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904\u201310.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"2422_CR206","doi-asserted-by":"publisher","first-page":"15460","DOI":"10.18632\/oncotarget.7102","volume":"7","author":"TH Heo","year":"2016","unstructured":"Heo TH, Wahler J, Suh N. Potential therapeutic implications of IL-6\/IL-6R\/gp130-targeting agents in breast cancer. Oncotarget. 2016;7(13):15460\u201373.","journal-title":"Oncotarget"},{"issue":"1","key":"2422_CR207","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/0300891618784790","volume":"105","author":"H Yousefi","year":"2019","unstructured":"Yousefi H, et al. IL-6\/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. Tumori. 2019;105(1):84\u201391.","journal-title":"Tumori"},{"issue":"7","key":"2422_CR208","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00262-023-03378-7","volume":"72","author":"N Nishiwaki","year":"2023","unstructured":"Nishiwaki N, et al. Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody. Cancer Immunol Immunother. 2023;72(7):2029\u201344.","journal-title":"Cancer Immunol Immunother"},{"issue":"25","key":"2422_CR209","doi-asserted-by":"publisher","first-page":"14764","DOI":"10.1074\/jbc.271.25.14764","volume":"271","author":"S Chevalier","year":"1996","unstructured":"Chevalier S, et al. Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein*. J Biol Chem. 1996;271(25):14764\u201372.","journal-title":"J Biol Chem"},{"issue":"23","key":"2422_CR210","doi-asserted-by":"publisher","first-page":"14728","DOI":"10.1073\/pnas.232562799","volume":"99","author":"M Hayashi","year":"2002","unstructured":"Hayashi M, et al. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci. 2002;99(23):14728\u201333.","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"2422_CR211","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.7150\/thno.73099","volume":"12","author":"S Cai","year":"2022","unstructured":"Cai S, et al. ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. Theranostics. 2022;12(16):7051\u201366.","journal-title":"Theranostics"},{"issue":"5","key":"2422_CR212","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.3390\/ijms23052535","volume":"23","author":"J Schneider","year":"2022","unstructured":"Schneider J, et al. Effects of ruxolitinib and calcitriol combination treatment on various molecular subtypes of breast cancer. Int J Mol Sci. 2022;23(5):2535.","journal-title":"Int J Mol Sci"},{"key":"2422_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175986","volume":"957","author":"Y Yu","year":"2023","unstructured":"Yu Y, et al. Regorafenib activates oxidative stress by inhibiting SELENOS and potentiates oxaliplatin-induced cell death in colon cancer cells. Eur J Pharmacol. 2023;957: 175986.","journal-title":"Eur J Pharmacol"},{"issue":"10395","key":"2422_CR214","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41\u201353.","journal-title":"Lancet"},{"issue":"3","key":"2422_CR215","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg JF, et al. Stat3 as an oncogene. Cell. 1999;98(3):295\u2013303.","journal-title":"Cell"},{"issue":"4","key":"2422_CR216","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3390\/cancers6041986","volume":"6","author":"M Spitzner","year":"2014","unstructured":"Spitzner M, et al. STAT3: a novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel). 2014;6(4):1986\u20132011.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2422_CR217","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/1078-0432.CCR-12-0792","volume":"18","author":"M Sen","year":"2012","unstructured":"Sen M, et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res. 2012;18(18):4986\u201396.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2422_CR218","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26(2):207\u201321.","journal-title":"Cancer Cell"},{"issue":"8","key":"2422_CR219","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/13543784.2017.1351941","volume":"26","author":"ALA Wong","year":"2017","unstructured":"Wong ALA, et al. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin Investig Drugs. 2017;26(8):883\u20137.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"2422_CR220","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","volume":"13","author":"J Schust","year":"2006","unstructured":"Schust J, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13(11):1235\u201342.","journal-title":"Chem Biol"},{"issue":"18","key":"2422_CR221","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1073\/pnas.0609757104","volume":"104","author":"K Siddiquee","year":"2007","unstructured":"Siddiquee K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA. 2007;104(18):7391\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"2422_CR222","doi-asserted-by":"publisher","first-page":"9623","DOI":"10.1073\/pnas.1121606109","volume":"109","author":"X Zhang","year":"2012","unstructured":"Zhang X, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci. 2012;109(24):9623\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2422_CR223","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2407-7-111","volume":"7","author":"C-L Chen","year":"2007","unstructured":"Chen C-L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer. 2007;7(1):111.","journal-title":"BMC Cancer"},{"issue":"1","key":"2422_CR224","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/sj.bjc.6604793","volume":"100","author":"B Fuh","year":"2009","unstructured":"Fuh B, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer. 2009;100(1):106\u201312.","journal-title":"Br J Cancer"},{"issue":"20","key":"2422_CR225","doi-asserted-by":"publisher","first-page":"9630","DOI":"10.1158\/0008-5472.CAN-07-1243","volume":"67","author":"SF Hussain","year":"2007","unstructured":"Hussain SF, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007;67(20):9630\u20136.","journal-title":"Cancer Res"},{"issue":"10","key":"2422_CR226","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.bcp.2010.01.001","volume":"79","author":"X Zhang","year":"2010","unstructured":"Zhang X, et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010;79(10):1398\u2013409.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2422_CR227","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/jcmm.17011","volume":"26","author":"DP Vageli","year":"2022","unstructured":"Vageli DP, et al. Targeting STAT3 prevents bile reflux-induced oncogenic molecular events linked to hypopharyngeal carcinogenesis. J Cell Mol Med. 2022;26(1):75\u201387.","journal-title":"J Cell Mol Med"},{"key":"2422_CR228","doi-asserted-by":"crossref","unstructured":"Wang Y, et al. Targeting IL-6\/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC. Cancer Lett. 2024;586:216612.","DOI":"10.1016\/j.canlet.2024.216612"},{"issue":"14","key":"2422_CR229","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.4161\/cc.25365","volume":"12","author":"YM Lin","year":"2013","unstructured":"Lin YM, et al. HIC1 interacts with and modulates the activity of STAT3. Cell Cycle. 2013;12(14):2266\u201376.","journal-title":"Cell Cycle"},{"issue":"1","key":"2422_CR230","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13046-020-01637-4","volume":"39","author":"Q Zhong","year":"2020","unstructured":"Zhong Q, et al. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R\/STAT3 signaling. J Exp Clin Cancer Res. 2020;39(1):132.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2422_CR231","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/biomedicines11030694","volume":"11","author":"S Laurino","year":"2023","unstructured":"Laurino S, et al. Role of IL-6\/STAT3 axis in resistance to cisplatin in gastric cancers. Biomedicines. 2023;11(3):694. https:\/\/doi.org\/10.3390\/biomedicines11030694.","journal-title":"Biomedicines"},{"key":"2422_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106703","volume":"189","author":"X Guan","year":"2023","unstructured":"Guan X, et al. Dual inhibition of MYC and SLC39A10 by a novel natural product STAT3 inhibitor derived from Chaetomium globosum suppresses tumor growth and metastasis in gastric cancer. Pharmacol Res. 2023;189: 106703.","journal-title":"Pharmacol Res"},{"issue":"26","key":"2422_CR233","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202200169","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, et al. SHF acts as a novel tumor suppressor in glioblastoma multiforme by disrupting STAT3 dimerization. Adv Sci (Weinh). 2022;9(26): e2200169.","journal-title":"Adv Sci (Weinh)"},{"key":"2422_CR234","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2022.06.001","volume":"26","author":"TW Kim","year":"2022","unstructured":"Kim TW, et al. Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. Mol Ther Oncolytics. 2022;26:1\u201314.","journal-title":"Mol Ther Oncolytics"},{"issue":"13","key":"2422_CR235","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1158\/0008-5472.CAN-12-2353","volume":"73","author":"T Ara","year":"2013","unstructured":"Ara T, et al. Critical role of STAT3 in IL-6\u2013mediated drug resistance in human neuroblastoma. Can Res. 2013;73(13):3852\u201364.","journal-title":"Can Res"},{"issue":"1","key":"2422_CR236","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ijc.33280","volume":"148","author":"E Beyranvand Nejad","year":"2021","unstructured":"Beyranvand Nejad E, et al. Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function. Int J Cancer. 2021;148(1):211\u201325.","journal-title":"Int J Cancer"},{"key":"2422_CR237","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173817","volume":"894","author":"S Xu","year":"2021","unstructured":"Xu S, et al. IL-6 promotes nuclear translocation of HIF-1\u03b1 to aggravate chemoresistance of ovarian cancer cells. Eur J Pharmacol. 2021;894: 173817.","journal-title":"Eur J Pharmacol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02422-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02422-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T08:39:02Z","timestamp":1732264742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02422-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":237,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2422"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02422-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"182"}}